Total trials
131
Active
26
Phase 3
0
Total enrollment
29,282
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis | — | — | — | — | — | 1 | |
| Blackcurrant (BC) extract | — | — | — | — | — | 2 | |
| Cannabidiol Oral Product | — | — | — | — | — | 1 | |
| Milk Polar Lipid-Rich Dairy Powder | — | — | — | — | — | 1 |
Next readouts
- 2026-05
- 2026-12-30
- 2027-01
- 2028-02
Top conditions
- Obesity16
- Hyperthermia7
- Hypertension6
- HIV Prevention Program6
- Cardiovascular Diseases5
- Weight Loss5
- HIV4
- Metabolic Syndrome4
Frequently asked questions about University of Connecticut
- How many clinical trials does University of Connecticut have on ClinicalTrials.gov?
- University of Connecticut is listed as the lead sponsor on 131 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Connecticut's trials are in Phase 3?
- 0 of University of Connecticut's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University of Connecticut focus on?
- University of Connecticut's most-studied conditions on ClinicalTrials.gov are Obesity, Hyperthermia, Hypertension, HIV Prevention Program, Cardiovascular Diseases.
- When are University of Connecticut's next clinical trial readouts?
- University of Connecticut has 4 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity”, expected around 2026-05.